Background. Donation after circulatory determination of death (DCDD), formerly non-heart-beating donation and donation after cardiac death, has been re-introduced into clinical practice in France since June 2006 as a potential solution to organ shortage, but this kidney transplantation programme is not popular yet, mainly because of logistical concerns and uncertainty about the long-term warm ischaemia impact on transplanted kidneys. Methods. Our institution started the DCDD programme in January 2007, following the national 'BioMedicine Agency' protocol. We only considered uncontrolled donors with an initial no-flow period (i.e. delay between collapse and external cardiac massage start) <30 min. A 5-min stand-off period was observed before declaring the death and performing in situ cold perfusion, and since January 2010, normothermic subdiaphragmatic extracorporeal membrane oxygenation. All kidneys were machine-perfused using the hypothermic pulsatile preservation system before transplantation. Morphologic assessment and perfusion indexes were used to assess the suitability for transplantation. Results. From January 2007 to December 2010, our team performed 58 kidney transplantations from uncontrolled Maastricht Category I and II donors. Mean recipient age was 47 6 9 years. Male/female ratio was 45/13. Mean waiting time on transplantation registry was 30 months (4-180). Mean cold ischaemia time was 13 h 40 min (7-18) and pulsatile perfusion time 8 h (1-16). We had three cases (5%) of primary non-function (PNF) and 95% of delayed graft function. There was no increase in biopsyproven acute rejection incidence (12.7%). Patient and graft survivals were 98 and 91.4%, respectively, at 1 year and 98 and 88%, respectively, at last follow-up. Estimated glomerular filtration rate ( Modification of Diet in Renal Disease formula) was 48 6 16 mL/min/1.73m 2 at 1 year and 48 6 15 mL/min/1.73m 2 at the last follow-up. Conclusions. DCDD kidneys are a valuable additional source of organs for transplantation. Our results show encouraging outcomes, which give rise to further interest in this donor pool. Respecting the national protocol is crucial to prevent PNF and deleterious warm ischaemia effect on transplanted kidney.
Introduction
One answer to the problem of organ shortage is the use of kidneys from donation after circulatory determination of death (DCDD), also known as donation after cardiac death and non-heart-beating donation [1, 2] . The distinction between donation after brain death (DBD), also known as heart-beating donation, and DCDD lies in the criteria used to diagnose death; brain stem death criteria are used in the former, whereas cardio-circulatory criteria are applied to the latter [1] .
Kidneys from DCDD suffer a period of warm ischaemic damage, which comprises an initial no-flow period (i.e. the time between cardiopulmonary arrest and initiation of external cardiac massage) and a low-flow period (i.e. during cardiac massage). The initial warm ischaemic time (WIT) (i.e. no-flow period) is often of unknown duration and is a damaging event since there is no perfusion to support renal cell homeostasis. The two broad categories of DCDD are controlled and uncontrolled donors [3] . The former are those donors in whom cardiac arrest is awaited by the transplant team; initial WIT is generally shorter than for the uncontrolled donors, who typically present through emergency departments and are referred because of unsuccessful cardiopulmonary resuscitation.
This source of kidneys has not been widely accepted because of various important legal and logistical concerns, and the fact that the prolonged WIT may make the kidneys unsuitable for transplantation. The consequences of the prolonged WIT are increased rates of primary non-function (PNF) and a high rate of delayed graft function (DGF) as a result of acute tubular necrosis. The influence of DGF on long-term renal allograft survival is controversial. A number of studies [4, 5] , but not all [6, 7] , have demonstrated that DGF may be detrimental to long-term outcome of kidney allograft in general. However, despite the high rate of DGF in DCDDs, the majority of studies have shown favourable comparisons with DBD in terms of graft survival and function [2, 8] .
Tailored strategies for preservation, viability prediction and immunosuppression for DCDD kidneys have the potential to maximize the number of available organs. In renal transplantation centres using DCDD kidneys, it has been shown that this organ source may be capable of increasing the donor pool up to 20-30% [9] .
Despite a significant increase in procurement and transplantation activities observed in France in the last 10 years, the shortage in grafts is on the rise and demand keeps being much higher than supply. From 1968 until 2006, procurement was limited to brain dead donors. DCDD kidney retrieval has been introduced into clinical practice in France since June 2006, after a law modification in August 2005, authorizing procurement of organs from the so-called 'uncontrolled' DCDD donors (Maastricht Categories I, II and IV donors) [3] .
To date, 13 French centres are involved in the DCDD transplantation programme, in a unique national framework protocol issued by the Agency of Biomedicine (Agence de la BioMédecine, ABM) [10, 11] , the French national regulatory authority for organ and tissue procurement and transplantation.
Our institution, Saint Louis Hospital (Assistance Publique -Hôpitaux de Paris, France), a tertiary teaching hospital, was the second to obtain authorization in December 2006 [12, 13] .
We herein report the preliminary results of the first 4 years of DCDD renal transplantation at our institution, one of the pioneer national centres in this type of transplantation.
Materials and methods
The DCDD programme started at Saint Louis Hospital on January 2007 using machine perfusion. All adult patients having in-hospital or out-ofhospital refractory circulatory arrest were considered eligible.
According to the French national transplantation supervision institution (ABM), donors' inclusion criteria were age between 18 and 55 years; a witnessed cardiac arrest of uncontrolled donors (Categories I, II and IV according to the Maastricht classification); initial no-flow period <30 min; refractoriness of circulatory arrest after at least 30 min of optimal cardiopulmonary resuscitation; absence of evidence of cancer and no known renal disease, no diabetes and no hypertension.
Recipient's inclusion criteria were age between 18 and 60 years, waiting for first kidney transplantation, at low immunologic risk [0% panelreactive antibody (PRA) by sensitive methods] and without major vascular disease.
Donor resuscitation was performed according to the international standard guidelines and using an external cardiac massage machine (AutopulseÒ; Zoll, Chelmsford, MA). A 5-min stand-off period was observed before declaring the death and then cardiac massage was resumed. After consultation of the automated National Registry for organ donation refusals, an aortic double-balloon triple-lumen catheter (Gillot's cannula) [14] was surgically inserted, through an inguinal incision, and kidneys were perfused in situ with a cold fourth generation preservation solution (IGL-1Ò; Institut Georges-Lopez, France). Since January 2010, in situ preservation was frequently done with a modified (subdiaphragmatic) normothermic extracorporeal membrane oxygenation (ECMO), in view of the better kidney functional results suggested by the Spanish reports, and to permit liver procurement [15, 16] . Total warm ischaemia (i.e. delay between cardiac arrest and start of in situ perfusion; the sum of no-flow and low-flow periods) was not to exceed 150 min. Kidneys were withdrawn <180 min after in situ cooling or <240 min after ECMO start [12] .
Fifty kidneys were harvested locally and eight kidneys imported. All DCDD kidneys were machine perfused using the hypothermic (1-4°C) pulsatile perfusion over at least 2 h (LifeportÒ; Organ Recovery System, Des Plaines, IL). The organ preservation solution used in this device was a University of Wisconsin solution (KPS-1Ò; Organ Recovery System). Initial perfusion pressure was 30 mmHg in our protocol and was eventually modified every hour according to resistive indexes (RIs): a decrease of 5 mmHg (until a minimum of 20 mmHg) if RI <0.3; no change if RI between 0.3 and 0.6; increase of 5 mmHg (until a maximum of 40 mmHg) if RI >0.6.
The viability of the retrieved kidney was assessed by morphologic criteria and intrarenal RI (<0.40 after 2 h of machine perfusion). A graft biopsy was performed, but the results were not available before the transplantation.
All DCDD kidney transplantation patients received depleting antibody induction with rabbit antithymocyte globulin (rATG, ThymoglobulinÒ; Genzyme Corp.) at a dose of 1.25 mg/kg/day (maximum dose, 125 mg) for 7-10 days, based on actual body weight. The first dose of rATG was given intraoperatively and subsequent rATG infusions were administered daily for a minimum of 7 and a maximum of 10 doses, depending on initial graft function. Maintenance immunosuppression consisted of cyclosporine and mycophenolate mofetil, without steroids, in accordance with our local immunosuppression protocol for low immunologic risk recipients.
PNF was defined as a permanent lack of function of the allograft from the time of transplantation. DGF was defined as the need for dialysis during the first week after transplantation with subsequent recovery of renal function. We defined that a patient recovered from acute tubular necrosis when no more dialysis was needed. The glomerular filtration rate (GFR) was calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) formula [17] .
Categorical data are summarized as proportions and percentages and continuous data are expressed as mean AE SD or, when data are not normally distributed, as median (range).
Results
From 1 January 2007 to 31 December 2010, our centre performed 58 kidney transplantations from DCDD.
Donor characteristics
The donors (n ¼ 43) fitted the Maastricht I and II categories in 86% (n ¼ 37) and 14% (n ¼ 6) of cases, respectively. Donor's characteristics and ischaemic times are presented in Table 1 .
Recipient characteristics
The characteristics of recipients are shown in Table 2 . Recipients were at low immunologic risk (0% PRA levels; no re-transplantation). Since the kidneys were allocated independently of tissue antigen typing, there was a relatively high degree of human leukocyte antigen mismatch.
Patient and graft outcome
Outcome after renal transplantation is shown in Table 3 . There were three cases of PNF: the first was due to an erroneous estimation of no-flow time (>30 min) in the initial phase of DCDD programme development; the second case was due to a non-immunologic graft vein thrombosis (vascular twist) and the third case of PNF happened in an imported kidney with some concerns about preservation conditions. Of the remaining 55 kidneys, all but two cases experienced a DGF, with a need of 8.17 AE 3.12 sessions of haemodialysis.
Two patients stopped their immunosuppressive treatment several months after transplantation and lost the graft due to an irreversible acute rejection; one patient had a poor graft function and needed dialysis by 1 year after transplantation and one patient died (with a functioning kidney) within 9 months of transplantation, due to a septic shock secondary to pneumonia.
At the last follow-up, of a mean duration of 44.2 AE 4.6 months, the patient and (uncensored) graft survivals were 98% (57/58) and 88% (51/58), respectively.
Renal function, as expressed by serum creatinine ( Figure  1 ) and estimated GFR (Figure 2 ), ameliorated progressively then reached a plateau~3 months after transplantation. 
Discussion
The use of DCDD kidneys to expand transplant programmes offers an answer to the problem of donor shortage. This source of kidneys is utilized by very few renal transplant units despite long-standing and growing evidence of equivalent graft function and survival compared with heart-beating donor organs [2, 8] . The majority of the USA and UK publications refer to 'controlled' donors of the Category III of Maastricht classification. The practice across Europe is very diverse. Spain and France carry out only 'uncontrolled' DCDD [18] . When compared to other European countries and the USA, the French DCDD programme has taken longer to get established but seems to meet the same enthusiasm, with an increasing number of annual transplantations and involved hospitals [19] .
Our preliminary results compare well with other published series of mainly uncontrolled DCDD donors transplantations in Europe [20] [21] [22] [23] . PNF rate does not exceed 5% (in comparison with 5.5-8.7% in other teams) [20] [21] [22] [23] [20, 23] . However, as already demonstrated [25, 26] , DGF does not seem to negatively impact long-term outcome of kidney grafts in DCDD, as it does in donation after brain death.
The incidence of acute rejection episodes (12.7%) was globally similar to our local experience and inferior to reported literature (24, 43.4, 50 and 52% in the series of Metcalfe et al., Weber et al., Sanchez-Fructoso et al. and Gok et al., respectively). This is probably due to the systematic use of anti-thymocyte globulin induction in a low immunologic risk population.
One-year graft survival (91.4%) is comparable to the four previously cited reports (81-89.6%) [20] [21] [22] [23] .
Similarly, our last follow-up graft survival (88%) seems comparable to 3-year graft survival in other series (77-89.6%) [21, 22] .
Renal function (48 mL/min/1.73m 2 ), as estimated with the use of the MDRD formula, is also comparable to other series dealing with DCDD donors (44.2 mL/min at 3 months in the series of Gok et al. [21] ).
In conclusion, our study shows that excellent kidney transplantation results can be obtained from uncontrolled DCDD donors as guided by the national 'ABM' French protocol. Respecting the national 'ABM' protocol is probably crucial to guarantee low PNF incidence and minimal warm ischaemic damage to transplanted kidneys.
In addition, perennity of this activity is highly dependant on a motivated team (especially surgeons and transplant coordinators).
These results are, to our knowledge, the first to have published a French experience in DCDD kidney transplantation. They may provide a new basis for the re-evaluation of this source of organs by transplantation centres and by legislative bodies and rise hope to extend the French DCDD protocol to liver and eventually other organs transplantation [27] . 
